Nobel Biocare - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 2,095,088 | 2,737,105 | 1,624,006 | 2,281,391 | 1,918,756 | 2,446,261 | 2,098,995 | 2,624,272 |
| Profit before tax | 62,202 | 93,517 | 89,809 | -2,301 | 16,702 | 70,637 | -46,139 | 244,152 |
| Net profit | 51,874 | 78,166 | 73,043 | -5,391 | 16,001 | 62,993 | -42,779 | 176,617 |
| Equity | 577,244 | 655,411 | 728,454 | 723,111 | 739,183 | 796,563 | 795,868 | 904,494 |
| Liabilities | 333,946 | 826,576 | 474,416 | 623,533 | 730,130 | 1,092,963 | 724,687 | 939,122 |
| Non-current assets | 17,596 | 20,076 | 15,476 | 33,063 | 29,268 | 38,634 | 38,251 | 31,637 |
| Current assets | 932,797 | 1,540,279 | 1,206,633 | 1,352,143 | 1,486,100 | 1,935,078 | 1,559,790 | 1,916,320 |
| Total assets | 950,393 | 1,560,355 | 1,222,109 | 1,385,206 | 1,515,368 | 1,973,712 | 1,598,041 | 1,947,957 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 594,535 | 569,696 | 634,709 |
| Social insurance contributions | - | - | - | - | - | 140,988 | 160,679 | 176,509 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +9.8% | +30.6% | -40.7% | +40.5% | -15.9% | +27.5% | -14.2% | +25.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.5% | 5.0% | 6.0% | -0.4% | 1.1% | 3.2% | -2.7% | 9.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 9.0% | 11.9% | 10.0% | -0.7% | 2.2% | 7.9% | -5.4% | 19.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.5% | 2.9% | 4.5% | -0.2% | 0.8% | 2.6% | -2.0% | 6.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.0% | 3.4% | 5.5% | -0.1% | 0.9% | 2.9% | -2.2% | 9.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.6 | 1.3 | 0.7 | 0.9 | 1.0 | 1.4 | 0.9 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 273,271 | 360,939 | 203,001 | 276,532 | 179,883 | 212,718 | 186,577 | 273,838 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nobel Biocare - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-08-19 | 2024-08-21 | 2196.00 |
| 2023-07-18 | 2023-07-19 | 7284.44 |
| 2022-11-28 | 2022-12-15 | 3006.73 |
| 2022-11-21 | 2022-11-27 | 9873.33 |
| 2022-11-17 | 2022-11-18 | 9873.33 |
| 2022-07-18 | 2022-07-25 | 66.49 |
| 2021-10-18 | 2021-10-21 | 3779.86 |
Nobel Biocare - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-15 | 2026-04-15 | 4876.57 |
| 2025-12-18 | 2025-12-29 | 1.18 |
| 2025-06-10 | 2025-06-10 | 0.68 |
| 2025-06-06 | 2025-06-09 | 565.68 |
| 2025-06-02 | 2025-06-05 | 564.93 |
| 2025-05-29 | 2025-06-01 | 564.18 |
| 2024-11-28 | 2024-11-28 | 13254.07 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nobel Biocare, UAB (code 300521262) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 2.62 million in revenue, up 25.0% year on year and 7.3% over two years. Net profit improved to EUR 176.6 thousand, compared with a loss of EUR 42.8 thousand in 2024 and profit of EUR 63.0 thousand in 2023, showing a clear recovery in profitability. The 2025 profit margin was 6.7%, versus -2.0% in 2024 and 2.6% in 2023. On the balance sheet, total assets reached EUR 1.95 million, equity EUR 904.5 thousand, and liabilities EUR 939.1 thousand. The equity ratio stood at 46.4%, while debt-to-equity was 1.04. Return on equity was 19.5% and return on assets 9.1%. Asset turnover was 1.35x, indicating efficient use of assets. With revenue per employee of EUR 291.6 thousand and profit per employee of EUR 19.6 thousand, the 2025 results point to improved operating performance after the weaker 2024 result.